关节置换术患者β-内酰胺类过敏筛查以改进手术预防用药实践
本研究在关节置换术患者中通过电子最佳实践警示(BPA)将报告有β-内酰胺类过敏史(HOBA)者转诊至药物过敏门诊(DAC)进行筛查,161例中140例(87%)接受青霉素皮试(PST),139例(99%)皮试阴性;经DAC评估的患者使用头孢唑林的比例显著高于未评估者(90% vs 77%),且无围手术期不良反应。作者认为关节置换外科医生应考虑实施过敏筛查项目以促进抗菌药物管理。
要点
- 161例报告β-内酰胺类过敏史的关节置换患者经BPA转诊至DAC,140例(87%)接受青霉素皮试,139例(99%)皮试阴性。
- 经DAC评估的患者中145例(90%)可安全使用头孢唑林,任何手术预防方案中使用头孢唑林的比例为90%,高于未评估者的77%。
- 经DAC评估的患者使用非β-内酰胺类抗生素的比例为16%,显著低于未评估者的27%。
核心结论
- 使用BPA和DAC进行β-内酰胺类过敏筛查可促进头孢唑林作为标准手术预防用药的使用,关节置换外科医生应考虑实施过敏筛查项目以促进抗菌药物管理。
研究设计与样本
- 本研究为在作者所在机构开展的研究,2013年2月至2015年5月期间共161例报告有β-内酰胺类过敏史的关节置换患者经BPA转诊至DAC,根据病史接受青霉素皮试、β-内酰胺类抗生素药物激发试验或未干预。
主要发现
- 161例中140例(87%)接受青霉素皮试,其中139例(99%)皮试阴性,提示无青霉素过敏。
- 经DAC评估的患者中145例(90%)可安全使用头孢唑林,经DAC评估者任何手术预防方案中使用头孢唑林的比例为90%,显著高于未评估者的77%,且无围手术期不良反应。
- 经DAC评估者使用非β-内酰胺类抗生素的比例为16%,显著低于未评估者的27%。
- 研究期间,报告有β-内酰胺类过敏史的骨科手术患者中头孢唑林总体使用率超过84%。
关键数值与推荐
- 161例报告有β-内酰胺类过敏史的患者中,140例(87%)接受青霉素皮试,139例(99%)皮试阴性。
- 经DAC评估的患者中145例(90%)可安全使用头孢唑林;经DAC评估者使用头孢唑林的比例为90%,未评估者为77%。
- 经DAC评估者使用非β-内酰胺类抗生素的比例为16%,未评估者为27%。
临床怎么用
- 作者认为,关节置换外科医生应考虑实施过敏筛查项目以促进抗菌药物管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The reliability of patient-reported penicillin allergies has been disputed. A Drug Allergy Clinic (DAC) was established at our institution in combination with an electronic best practice alert (BPA) in the Orthopedic Clinic. Joint arthroplasty patients with a reported history of beta-lactam allergy (HOBA) were preoperatively referred via the BPA to the DAC. The purpose of this study was to determine the effectiveness of beta-lactam allergy screening in enabling the surgical team to optimize antimicrobial prophylaxis. METHODS: Between February 2013 and May 2015, 161 patients with a HOBA were referred to the DAC where they underwent penicillin skin testing (PST), a drug challenge to a beta-lactam antibiotic, and/or had no intervention depending on the history obtained. RESULTS: PST was performed on 140 of 161 (87%) patients. A negative PST was noted in 139 (99%) patients, indicating no penicillin allergy. Cefazolin was safe to use in 145 (90%) patients evaluated. Significantly more patients evaluated in the DAC vs those not seen got cefazolin in any surgical prophylaxis regimen (90% vs 77%) without any adverse perioperative reactions. Concurrently, the use of non-beta-lactam antibiotics was significantly less in the patients evaluated vs not evaluated (16% vs 27%). The overall use of cefazolin in orthopedic surgeries in patients with HOBA was >84% over the course of the study period. CONCLUSION: Beta-lactam allergy screening using a BPA and a DAC promotes the use of standard surgical prophylaxis with cefazolin. Joint arthroplasty surgeons should consider implementing allergy screening programs to promote antimicrobial stewardship.
引用
- McDanel DL, Azar AE, Dowden AM, et al. Screening for Beta-Lactam Allergy in Joint Arthroplasty Patients to Improve Surgical Prophylaxis Practice. J Arthroplasty. 2017. PMID: 28236547. doi:10.1016/j.arth.2017.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。